These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21138874)

  • 1. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.
    D'Antonio KB; Schultz L; Albadine R; Mondul AM; Platz EA; Netto GJ; Getzenberg RH
    Clin Cancer Res; 2010 Dec; 16(23):5908-13. PubMed ID: 21138874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.
    Zheng Q; Peskoe SB; Ribas J; Rafiqi F; Kudrolli T; Meeker AK; De Marzo AM; Platz EA; Lupold SE
    Prostate; 2014 Dec; 74(16):1655-62. PubMed ID: 25252191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyr61 is a potential prognostic marker for prostate cancer.
    Terada N; Kulkarni P; Getzenberg RH
    Asian J Androl; 2012 May; 14(3):405-8. PubMed ID: 22343491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.
    Chaux A; Peskoe SB; Gonzalez-Roibon N; Schultz L; Albadine R; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Mod Pathol; 2012 Nov; 25(11):1543-9. PubMed ID: 22684219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
    De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
    Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.
    Wei J; Yu G; Shao G; Sun A; Chen M; Yang W; Lin Q
    Oncotarget; 2016 May; 7(21):31067-78. PubMed ID: 27105510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence.
    Cao D; Kibel AS; Gao F; Tao Y; Humphrey PA
    Am J Surg Pathol; 2010 Jul; 34(7):994-1001. PubMed ID: 20505501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.
    Magheli A; Rais-Bahrami S; Trock BJ; Humphreys EB; Partin AW; Han M; Gonzalgo ML
    Urology; 2008 Dec; 72(6):1246-51. PubMed ID: 18387658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma.
    Rioux-Leclercq NC; Chan DY; Epstein JI
    Urology; 2002 Oct; 60(4):666-9. PubMed ID: 12385930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
    Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
    D'Antonio KB; Toubaji A; Albadine R; Mondul AM; Platz EA; Netto GJ; Getzenberg RH
    J Urol; 2010 Apr; 183(4):1604-10. PubMed ID: 20172544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
    Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
    Cole AI; Morgan TM; Spratt DE; Palapattu GS; He C; Tomlins SA; Weizer AZ; Feng FY; Wu A; Siddiqui J; Chinnaiyan AM; Montgomery JS; Kunju LP; Miller DC; Hollenbeck BK; Wei JT; Mehra R
    J Urol; 2016 Aug; 196(2):405-11. PubMed ID: 26920466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.